Adaptive Biotechnologies (ADPT) Cash from Financing Activities (2018 - 2026)

Adaptive Biotechnologies has reported Cash from Financing Activities for 9 years, with the latest figure at $7.5 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 37.59% year-over-year to $7.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.5 million (up 474.58% YoY) and the FY2025 annual result came in at $30.4 million, up 12515.35% from the prior year.
• Cash from Financing Activities slipped to $7.5 million in Q1 2026 per ADPT's latest filing, from $21.7 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $125.5 million in Q3 2022 and troughed at $6000.0 in Q4 2022.
• A 5-year average of $10.2 million and a median of $1.5 million in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities plunged 99.99% in 2023, then soared 16953.54% in 2025.
• Over 5 years, Cash from Financing Activities stood at $6000.0 in 2022, then jumped by 1350.0% to $87000.0 in 2023, then surged by 45.98% to $127000.0 in 2024, then jumped by 16953.54% to $21.7 million in 2025, then sank by 65.37% to $7.5 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $7.5 million, $21.7 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.